(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 May 2002 (30.05.2002)

PCT

(10) International Publication Number
WO 02/042425 A3

(51) International Patent Classification[7]: C07H 21/04, C12Q 1/68, C12N 15/85

(21) International Application Number: PCT/US01/45178

(22) International Filing Date:
20 November 2001 (20.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/721,822 22 November 2000 (22.11.2000) US

(71) Applicants *(for all designated States except US)*: **ISIS PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US). **UNIVERSITY OF VIRGINIA PATENT FOUNDATION** [US/US]; 1224 W. Main Street, Suite 1-110, Charlottesville, VA 22903 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **WEBER, Michael, J.** [US/US]; 1855 Westview Road, Charlottesville, VA 22908 (US). **WYATT, Jacqueline, R.** [US/US]; 1065 Hymettus Avenue, Encinitas, CA 92024 (US). **COWSERT, Lex, M.** [US/US]; 1299 Parrott Drive, San Mateo, CA 94402 (US).

(74) Agents: **LICATA, Jane, Massey** et al.; Licata & Tyrell P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
6 September 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/042425 A3

(54) Title: ANTISENSE MODULATION OF MP-1 EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MP-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MP-1. Methods of using these compounds for modulation of MP-1 expression and for treatment of diseases associated with expression of MP-1 are provided.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/45178

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04; C12Q 1/68; C12N 15/85

US CL : 435/6, 325, 375; 514/44; 536/23.1, 24.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 325, 375; 514/44; 536/23.1, 24.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, MEDLINE, CAPLUS, EMBASE, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BRANCH, A.D. A good antisense molecule is hard to find. TIBS. February 1998. Vol. 23, pages 45-50.	1-17
A	GEWIRTZ et al. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc. Natl. Acad. Sci., USA. April 1996, Vol. 93, pages 3161-3163.	1-17

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

10 April 2002 (10.04.2002)

Date of mailing of the international search report

13 MAY 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Andrew Wang

Telephone No. 703-308-0196

Form PCT/ISA/210 (second sheet) (July 1998)